Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eisai

Japan approves simple Alzheimer’s blood test

TOKYO: Japan’s health ministry has approved one of the world’s first blood test kits to detect signs of Alzheimer’s disease, paving way for a simpler and speedier diagnosis of the brain-wasting ailment for which a blockbuster therapy is finally on the horizon.

Bangkok Post

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The Conversation

Is lecanemab the Alzheimer's drug that will finally make a difference?

The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review

The stock market rally showed strength on Fed chief Jerome Powell, but a hot jobs report pared gains. The S&P 500 is fighting for its 200-day.

Investors Business Daily

Lisa Jarvis: That blockbuster Alzheimer’s drug? It’s not a cure

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Tribune News Service

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Al Jazeera

Drug proven to slow decline in Alzheimer patients

Lecanemab, a newly developed drug, has showed promising results in clinical trials among Alzheimer patients

Manchester Evening News

Read news from The Economist, FT, and more,
with one subscription

New Alzheimer's drug faces uncertain regulatory path

The FDA will soon decide whether to approve Eisai's experimental drug lecanemab.

Axios

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

WEKU

New Alzheimer’s drug hailed as 'beginning of the end' in quest for treatment

Clinical results suggest that the disease progression can by slowed by 27%

Wales Online

Alzheimer's drug sparks hot debate over benefits as risks like brain bleeding emerge

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Tribune News Service

Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors

Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent."

Investors Business Daily

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment

Lecanemab was found to slow decline in patients’ memory and thinking.

The Independent UK

Drug slows Alzheimer's but can it make a real difference?

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

Investors Business Daily

Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A Setback

Axsome Therapeutics said its Alzheimer's treatment met the goals of a study, sending its shares into the stratosphere, while Biogen's Alzheimer's effort had a setback.

Wales Online

New Alzheimer's drug that slows cognitive decline could be available next year

People who are prescribed the drug will need regular MRI scans to check for brain swelling or bleeding

The Conversation

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Mayo Clinic expert offers perspective on experimental Alzheimer's disease drug

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

The New Daily

‘Historic moment’: Drug slows cognitive decline in Alzheimer’s

It's being widely reported that an experimental drug has slowed the cognitive decline and brain damage in Alzheimer's patients.

Benzinga

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session

Gainers

Benzinga

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

The Independent UK

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

The Guardian - UK

Success of experimental Alzheimer’s drug hailed as ‘historic moment’

Study shows cognition in early-stage patients on lecanemab declines by 27% less than those on placebo

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.